Dr. Kai Hu
oncology, hematology, lymphoma, myeloma
oncology, hematology, lymphoma, myeloma
Overview
Country, City
China, Beijing
Health facility
Beijing GoBroad Boren Hospital
Medical unit
Department of lymphoma and myeloma
About the doctor
Skills & Expertise
lymphoma
bcell
bcell lymphoma
cell therapy
large bcell lymphoma
large bcell
cart cell
myeloma
cart cell therapy
car t cells
transplantation
lymphoma myeloma
t cells immunotherapy
oncology
immunotherapy
refractoryrelapsed bcell lymphoma
stem cell transplantation
cell transplantation
t cells
cells immunotherapy
nonhodgkins
hematology lymphoma
adult lymphoma
lymphoma efficacy
hematologic oncology
cd20sdcart therapy
cd19 cart
pbmcs cart
lymphoma primary
hematology
cryopreservation
cd19 cart treatment
oncology hematology lymphoma
autologous stem cell
hematopoietic stem cell
aggressive bcell lymphoma
t cell therapy
bcell nonhodgkin lymphoma
transplantation cell therapy
lymphoma cd19 cart
tcell therapy treatment
burkitt lymphoma
cryopreservation pbmcs cart
relapsedrefractory nonhodgkins lymphoma
pbmcs cart therapy
tcell lymphoma
nonhodgkins lymphoma
oncology hematology
nonhodgkin lymphoma
tcell therapy
Resume
CV (Curriculum Vitae)
Experience
- Director of the adult lymphoma and myeloma department at the Beijing GoBroad Boren Hospital
Awards & Memberships
- Member of the first China T-cell Lymphoma Working Group of the Chinese Anti-Cancer Association Hematologic Oncology Committee
- Member of the Health Science Popularization Professional Committee of the China Health Care Association
- Member of the Hematopoietic Stem Cell Transplantation and Cell Therapy Professional Committee of the China Medical Education Association
- Expert member of the Beijing Medical Association's municipal "hub-type" social organization
Languages
English
Chinese
Publications
Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.
5 September, 2024
Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure
25 June, 2024
EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial.
1 June, 2024
FAQ
Where does the doctor practice?
Dr. Kai Hu works at Beijing GoBroad Boren Hospital.
What is the specialization of Dr. Kai Hu?
The primary specialization of the doctor is oncology, hematology, lymphoma, myeloma.
What is the rating of the doctor?
Dr. Kai Hu is rated as 9.70 by AiroMedical.
Dr. Kai Hu
Get individual treatment plan and cost estimate. Non-binding 100% free assessment.
© Dr. Kai Hu